Recombinant thymosin β4 (Northland)

重组胸腺素β4（诺思兰德）

Report date: 2026/05/18 20:02:07

Base Information

Drug NameRecombinant thymosin β4 (Northland)
Drug Alias NameNL-005
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionActin inhibitors
TargetsActin
Therapy Area/IndicationsST Elevation Myocardial InfarctionAnterior Wall Myocardial InfarctionMyocardial Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Northland Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Northland Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsST Elevation Myocardial InfarctionAnterior Wall Myocardial InfarctionMyocardial Infarction
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A